Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 1, 2010, Pages 134-142

  Zinman, Bernard ^a   Haffner, Steven M ^b   Herman, William H ^c   Holman, Rury R ^d   Lachin, John M ^e,j   Kravitz, Barbara G ^f   Paul, Gitanjali ^f   Jones, Nigel P ^g   Aftring, R Paul ^f   Viberti, Giancarlo ^h   Kahn, Steven E ⁱ   Kahn, Steven ^j   Haffner, Steven ^j   Herman, William ^j   Aftring, Paul ^j   Jones, Nigel ^j  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; GLIBENCLAMIDE; METFORMIN; PEPTIDE; PROCOLLAGEN TYPE 1 N PROPEPTIDE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 75149119236     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0572     Document Type: Article

References (18)

1. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
2. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G 2008 Rosiglitazone- associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845-851
3. Takeda Pharmaceuticals 2007 Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus (letter to health care providers)
4. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226-1235
5. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 74:357-371
6. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ 2007 Activation of peroxisome proliferator-activated receptor γ(PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148: 903-911
7. Grey A 2008 Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19:129-137
8. Lecka-Czernik B, Suva LJ 2006 Resolving the two "bony" faces of PPAR-γ. PPAR Res 2006:27489
9. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B 2007 Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148: 2669-2680
10. Sottile V, Seuwen K, Kneissel M2004 Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARγ agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75: 329-337
11. Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demirag N 2007 Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92:3523-3530
12. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP 2008 Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 93:1696-1701
13. Grey A, BollandM,Gamble G, Wattie D, Horne A, Davidson J, Reid IR 2007 The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310
14. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI 2002 A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 25:1737-1743
15. HochbergY1988Asharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802
16. McCulloch CE, Searle SR 2001 Generalized, linear and mixed models. New York: John Wiley, Sons
17. Okazaki R, Miura M, Toriumi M, Taguchi M, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi A 1999 Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795-801
18. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T 2003 Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21:166-171